Tag: AstraZeneca

September 8, 2023

Artificial intelligence tools have drawn the interest of many drugmakers hoping to use it to unearth new therapeutic targets. Launched in 2015, Verge has raised over $100 million from a variety of investors, including the asset management firm Blackrock and […]

July 28, 2023

Once a bystander in the field of genetic medicine, AstraZeneca has started to make its ambitions clear over the last couple years. The company stuck to the sidelines, while drugmakers such as Novartis, Bristol Myers Squibb and Gilead made significant […]

May 18, 2023

Revvity, a provider of health sciences services, entered a new license agreement with AstraZeneca for the technology underlying its Pin-point base editing system, a next-generation modular gene editing platform with a strong safety profile. The Pin-point system and the underlying […]

January 13, 2023

The green light for the pre-filled, single-use pen version of Tezspire (tezepelumab) comes just four months after the TSLP inhibitor became the first biologic therapy for severe asthma to be cleared in the EU for use in all patients, and […]

January 11, 2023

Airsupra is part of a growing portfolio of new drugs that are helping offset wilting sales of older AstraZeneca respiratory medicines such as Pulmicort. It’s an essential therapeutic area for the British drugmaker; in the third quarter, respiratory and immunology […]

January 4, 2023

The start of the trial triggers a $5m milestone payment from AZ, which licensed AZD3152 from RQ Bio in May last year, and reinforces the financial position of the UK-based biotech to execute its four scientific programmes focused on viral […]

November 30, 2022

AstraZeneca has agreed to acquire Neogene Therapeutics for up to $320 million cash, the companies said Tuesday, in a deal intended to bolster the buyer’s portfolio of cancer-fighting cell therapies. Neogene specializes in discovering, developing, and manufacturing next-generation T-cell receptor […]

November 29, 2022

Once a fringe area of cancer research, cell therapy has exploded over the last decade. Since 2017, several treatments have come to market for blood cancers like leukemia and multiple myeloma, establishing cell therapy as a new class of medicines. […]

October 24, 2022

The dosing schedule of the combination has been referred to as the STRIDE (Single Tremelimumab Regular Interval Durvalumab) regimen, which includes a single dose of Imjudo 300mg added to Imfinzi 1500mg followed by Imfinzi every four weeks. The approval is […]

October 24, 2022

Tremelimumab has been approved by the FDA in the US for use in tandem with AZ’s PD-L1 inhibitor Imfinzi (durvalumab) to treat adults with unresectable hepatocellular carcinoma (HCC), the most common tumour type affecting the liver. The CTLA4 inhibitor – […]

October 3, 2022

AstraZeneca’s rare disease unit Alexion will acquire gene editing specialist LogicBio Therapeutics in a small buyout deal, the companies announced Monday. Under the terms of the agreement, Alexion will acquire all of LogicBio’s outstanding shares for $2.07 each, representing a […]

July 25, 2022

The Food and Drug Administration has agreed to quickly review AstraZeneca and Daiichi Sankyo’s drug Enhertu for treating metastatic breast cancer that expresses low levels of a protein known as HER2. If approved, the therapy would become the first targeted […]

July 13, 2022

Infectious disease experts from Asia reviewed data from the VIEW-hub database on vaccine use and impact, developed by John Hopkins Bloomberg School of Public Health and the International Vaccine Access Center. The findings from the study were reported by Expert […]

June 1, 2022

Until the launch of GSK’s Benlysta in 2011, people with lupus didn’t have a treatment option that targeted the disease’s underlying cause, relying instead on steroids and immunosuppressants to keep symptoms under control. AstraZeneca’s Saphnelo followed Benlysta to market in […]

May 23, 2022

Holding company Innoviva is acquiring late-stage antibiotic biotech Entasis Therapeutics, a 2015 AstraZeneca spin-out that just posted phase 3 results worthy of an FDA filing last year. Innoviva already owns about 60% of Entasis’ outstanding shares. Under the new definitive […]

May 5, 2022

The approval of Enhertu as a second-line option further establishes the drug’s growing role in breast cancer, where it’s quickly becoming a go-to treatment for the roughly 15% of patients with HER2-positive disease. First conditionally approved for third-line use in […]

April 15, 2022

As supplies of COVID-19 vaccines have become more plentiful in poor nations, many are tuning down certain shipments. A document from the World Health Organization’s global vaccine supply effort COVAX shows that low-income countries have declined millions of doses of […]

March 15, 2022

The FDA approval is specifically for the treatment of patients with BRCA-mutated HER2-negative high-risk early breast cancer who have already received chemotherapy treatment either before or after surgery. As the most diagnosed cancer worldwide, an estimated 2.3 million patients were […]

January 26, 2022

From the Pfizer/BioNTech and Oxford/AstraZeneca vaccines to GSK’s lifesaving antibody treatments, European innovation has played a crucial role in the global response to COVID-19. But while the pandemic triggered a boom in biotech initial public offerings, according to Hannah Kuchler, […]

January 20, 2022

Pfizer and Moderna are now two of the leading pharma companies in the U.S. when it comes to public image, thanks to their COVID vaccines. On the flip side, vaccine rivals J&J and AstraZeneca have seen their reputations plummet. This […]